Reckitt's operational turnaround is tracking — FY2025 Core LFL of +5.2%, adjusted operating margins of 26.7%, and £2.3bn returned to shareholders — but the stock trades near its 52-week low as the market reprices the Mead Johnson NEC litigation risk. A federal MDL bellwether trial is set for July 6, 2026 with 775+ cases pending, no provision has been disclosed, and a Chicago jury awarded $70M against a competitor in April 2026. The gap between the consensus analyst target of approximately 5,884 GBp and the current approximately 4,773 GBp implies the market is pricing in a litigation tail that most sell-side models have not yet fully quantified.
**NEC Litigation — Federal Bellwether Trial Scheduled July 6, 2026.** Reckitt's Mead Johnson unit faces a federal MDL bellwether trial (MDL No. 3026, N.D. Ill., Judge Pallmeyer) on July 6, 2026. As of early 2026, 775+ federal cases are pending alongside hundreds of additional state court cases. Prior verdicts: $60M against Reckitt (March 2024), $495M against Abbott (July 2024). Missouri appellate court overturned a prior Reckitt/Abbott win in March 2025 and ordered a new trial. In April 2026, a Chicago jury awarded $70M against Abbott — confirming sustained jury hostility. Bloomberg Intelligence estimates industry-wide NEC liability at up to $2.5B. Reckitt has disclosed no litigation provision.
**Stock at 52-Week Low Following Q1 2026 Results.** RKT.L traded at a 52-week low of 4,574 GBp on April 22, 2026 — the same day Q1 2026 results were published — down approximately 30% from the 52-week high of 6,514 GBp set on February 19, 2025. Prior negative catalyst: "less upbeat" FY2026 guidance on March 5, 2026 sent shares down 4%. Every major analyst price target (range: 4,949–8,085 GBp) sits above current levels.
**IFCN / Mead Johnson Remains Unsold — Active Hiring Signals Delay.** Management labeled the Infant Formula and Child Nutrition (IFCN/MJN) segment "non-core" and under strategic review, yet as of April 2026 LinkedIn shows an active posting for "Global Talent Director - Mead Johnson Nutrition" at Parsippany NJ. Either a sale is taking longer than signaled or the business is being resourced for standalone operation. The NEC litigation directly attaches to this unsold unit, creating compounded strategic and financial uncertainty.
**FY2025 Operational Beat — Core Reckitt +5.2%, £2.3bn Returned.** Core Reckitt delivered +5.2% LFL in FY2025 (Emerging Markets +14.6%), adjusted operating margin improved +90bps to 26.7%, group gross margin exceeded 60%, and adjusted diluted EPS reached 352.8p (+1.1%). Free cash flow was £1.7bn. A £1.6bn special dividend (235p/share, paid February 20, 2026) funded by Essential Home proceeds, combined with a £1bn buyback program, returned £2.3bn to shareholders.
**Essential Home Divested for $4.8B — Portfolio Reshaping Complete.** The household cleaning segment was sold to ECP for $4.8B, proceeds funding the special dividend. The remaining portfolio centers on 11 Powerbrands across Hygiene, Health, and Nutrition, now generating more than 80% of net revenue. Midterm LFL guidance stands at 4–5%. CEO Kris Licht framed the strategy as "simpler, sharper" at CAGNY 2026, with approximately 40% emerging market exposure as the structural growth lever.
**CEO Skin-in-Game Gap — Zero Open-Market Purchases Since Appointment.** Kris Licht (CEO since October 2023) received £5.81M total compensation in 2024, with 81% performance-linked. Estimated beneficial ownership is less than 0.012% of shares outstanding — less than approximately 77,000 shares. No open-market share purchases have been recorded since his October 2023 appointment, including during the approximate 30% price decline from peak. The RBGLY securities class action (class period January 13, 2021 – July 28, 2024) adds further governance uncertainty around legacy NEC disclosures.
**Analyst Consensus Implies ~23% Upside — Bear Camp Exists.** The sell-side consensus target of approximately 5,884 GBp (range: 4,949–8,085 GBp) implies approximately 23% upside from current levels. Jefferies (~5,900 GBp) and Citi (Buy, reinstated January 14, 2026) are constructive; Deutsche Bank is cautious (5,460 GBp). RBC downgraded to Sector Perform on January 16, 2026. JPMorgan trimmed to 5,800 GBp. Independent DCF models suggest intrinsic value of approximately 7,304 GBp — roughly 53% upside if NEC tail risk proves bounded.
**Emerging Markets Are the Growth Engine — ~40% Revenue, +14.6% FY2025 LFL.** China (Dettol double-digit LFL), India, and Southeast Asia drove EM LFL of +14.6% in FY2025. Durex posted +16.6% LFL. The Malaysia distribution deal closed in December 2025. EM exposure of approximately 40% is above the FMCG peer median and underpins the 4–5% midterm LFL target.
**Net Debt Leverage to Peak Mid-2026 at Approximately 2.5x.** Net debt/EBITDA was approximately 1.6x at FY2025 end. Management guided it will peak around 2.5x mid-2026 as the £1bn buyback draws down cash, before deleveraging. Total debt is approximately £6,987M. The 60%+ gross margin and £1.7bn annual FCF provide sufficient coverage, though a large NEC settlement coinciding with the leverage peak could stress capital allocation.
The July 6, 2026 federal bellwether trial is the most consequential forward event on the RKT.L calendar. The prior news flow from March 2025 through April 2026 shows a one-way deterioration in litigation sentiment: each successive court development has worsened — not improved — Reckitt's legal position.
Every published target sits above the current market price. The bear case (Deutsche Bank, 5,460 GBp) still implies approximately 14% upside; the DCF-based bull case (~7,304 GBp per independent model) implies approximately 53%. The analytical spread is unusually wide for a FTSE 100 name — NEC liability is the unresolved variable that prevents consensus convergence.
CEO Licht's 81% performance-linked pay aligns compensation with Powerbrand growth metrics, but the absence of personal equity conviction — less than 0.012% ownership and no open-market purchases across a approximately 30% drawdown — weakens the "skin in game" narrative. Licht was appointed in October 2023, post-dating the RBGLY securities class period (January 2021 – July 2024), so he carries no personal legacy liability from the NEC disclosure controversy, but he also bears none of the downside from the stock decline on a personal net-worth basis.
Reckitt has disclosed no litigation provision in its FY2025 accounts. Bloomberg Intelligence estimates total industry NEC liability at up to $2.5B. The July 6, 2026 bellwether trial names Reckitt's Mead Johnson directly and is the most consequential near-term event for the investment case. Verdicts shown in USD; blank cells indicate no financial verdict.
Reckitt's 9.74x P/E represents a 40–60% discount to the FMCG peer group. The operational fundamentals — 26.7% adjusted operating margin, 60%+ gross margin, £1.7bn FCF — are peer-competitive and in several cases superior. The discount is driven by the NEC litigation quantum uncertainty and IFCN disposal overhang, not by operational underperformance. Haleon (HLN.L) is the closest portfolio and governance comparator (OTC healthcare, UK-listed demerger); HLN's higher multiple reflects a cleaner US legal profile. The peer table shows Reckitt's dividend yield is comfortably the highest in the group — an income-investor anchor that partially offsets litigation risk.